The prescribing clinician determines whether treatment is appropriate based on individual medical history, current medications, and cardiovascular status
Whether the heart-rate and irregular-heartbeat findings translate into more or fewer serious heart events over 5 to 10 years isnt yet known
Jang Won Son, Carel W le Roux, Matthias Blher, Michael A Nauck, Soo Lim Endocrine Reviews , First published online October 7, 2025, bnaf036 The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity
The 2025 GLP-1 guidelines have positioned these drugs at the forefront of type 2 diabetes management, reflecting their multifaceted benefits
The authors reported that retatrutide treatment for 48 weeks resulted in substantial reductions in body weight compared with placebo [1]
A properly reconstituted solution from a high-quality source like Real Peptides will be perfectly clear